Chemoradiation in Unresectable Oral Cavity Cancer: A Myth or Reality!
| Autor: | Atanu Bhattacharjee, Kumar Prabhash, Nilesh Sabale, Sarbani Ghosh-Laskar, Hollis Dsouza, Vanita Noronha, Abhishek Mahajan, Amit Kumar, Amit Joshi, Vijay Patil |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
borderline resectable
Oncology Cancer Research medicine.medical_specialty unresectable Original Article: Head and Neck Cancer Oral cavity 03 medical and health sciences 0302 clinical medicine Borderline resectable Internal medicine medicine Overall survival In patient Progression-free survival chemoradiation RC254-282 030304 developmental biology 0303 health sciences business.industry Neoplasms. Tumors. Oncology. Including cancer and carcinogens Cancer oral cancer medicine.disease Confidence interval 030220 oncology & carcinogenesis Oral Cancers business |
| Zdroj: | South Asian Journal of Cancer, Vol 09, Iss 04, Pp 195-198 (2020) South Asian Journal of Cancer |
| ISSN: | 2278-4306 2278-330X |
| DOI: | 10.1055/s-0041-1728225 |
| Popis: | Objective Earlier studies have shown that chemoradiation (CTRT) has benefits in the head-and-neck cancer, but how far it is true for oral cavity subset that has not been exactly explored. Keeping the null hypothesis as CTRT has no benefit in oral cavity cancer, we studied the outcome of patients undergoing chemoradiation in unresectable oral cavity cancers. The aim of this study is to study whether overall survival (OS) increases with chemoradiation in unresectable oral cavity cancers. Patients and Methods Between December 2014 and February 2017, 23 patients aged 18 years and above were planned chemoradiation for unresectable oral cavity cancer and were included for this analysis. Results The median age of patients was 43 years and all patients were addicted to tobacco. In total, 12 of 23 (52%) completed CTRT. One patient (1/23) was alive at the time of final analysis with median OS of 5.83 (2.73–9.60) months. The median progression free survival and OS in patients who completed chemoradiation were 6.42 months (95% confidence interval [CI]: 3.67–10.53) and 8.9 months (95% CI: 4.4–23.07), respectively. Conclusion CTRT has a limited role in unresectable oral cancers. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|